MedPath

Nucorion Pharmaceuticals, Inc.

Nucorion Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2015-01-01
Employees
-
Market Cap
-
Website
http://www.nucorionpharma.com

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Phase 1
Completed
Conditions
Chronic Hepatitis B
Interventions
Drug: NCO-48 Fumarate 4 mg
Drug: NCO-48 Fumarate 20 mg
First Posted Date
2020-11-16
Last Posted Date
2023-01-04
Lead Sponsor
Nucorion Pharmaceuticals, Inc.
Target Recruit Count
21
Registration Number
NCT04629976
Locations
🇺🇸

National Institute of Clinical Research, Inc, Monterey Park, California, United States

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Phase 1
Completed
Conditions
Hepatitis B
Interventions
First Posted Date
2020-03-16
Last Posted Date
2020-11-03
Lead Sponsor
Nucorion Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT04309526
Locations
🇺🇸

Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.